Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatmentexperienced patients with drugresistant hiv infection: Week 96 results of the benchmrk 1 and 2 phase III trials

BENCHMRK-1 and -2 are ongoing double-blind phase III studies of raltegravir in patients experiencing failure of antiretroviral therapy with triple-class drug-resistant human immunodeficiency virus infection. At week 96 (combined data), raltegravir (400 mg twice daily) plus optimized background therapy was generally well tolerated, with superior and durable antiretroviral and immunological efficacy, compared with optimized background therapy alone.